Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

University of South Florida Sues Drug Maker Over Research Patent Payment

By Drug Discovery Trends Editor | July 9, 2015

The University of South Florida filed a federal lawsuit against a California pharmaceutical company, over a 2012 settlement agreement ending a large lawsuit over Alzheimer’s research patents.

The school contends in its June 30 lawsuit that CoMentis Inc. of South San Francisco agreed in 2012 to pay $450,000 as part of a years-long legal dispute brought from the Alzheimer’s Institute of America (AIA), and involving Eli Lilly, the Oklahoma Medical Research Foundation, Avid Radiopharmaceuticals, and the University of Pennsylvania.

But CoMentis never paid, they contend in the complaint, filed in the U.S. District Court for the Middle District of Florida.

“CoMentis has filed to make the required contingent payment and has indicated in writing to USF that it does not intend to do so,” the lawsuit says. “Those writings make it clear that CoMentis at no time intended to honor its obligations under the Settlement Agreement.”

The university is seeking the $450,000, plus attorney’s fees and costs, the court documents show.

The initial litigation was brought in 2010 by the Alzheimer’s Institute of America against several of the companies. At the heart of the lawsuits were four patents for mouse mutations, nucleic acid combinations, and other tools to study the brain disease, developed by Michael J. Mullan, a USF researcher, according to the court documents.

The AIA had claimed that Mullan had assigned the patents to the Institute – but the court found that since the scientist was an employee of the school, “USF and not Dr. Mullan had an ownership interest in the Asserted Patents under Florida law,” according to the filing.

CoMentis and USF both did not return messages requesting comment on the latest court filing.

All the other defendants who signed settlements in 2012 paid their amounts due – totaling more than $1 million, according to the USF filing.


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE